Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear. Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.

<p>Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear.</p>
<p>Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.</p>


Akouos

Founded: 2016
Location: Boston, MA
Employee range: 51-100
Clinical stage: Clin1/Clin2
Therapy area: OTOF-mediated hearing loss
Drug types: OTO, GEN, RAR, NEU, PED
Lead product: AK-OTOF
Funding: 100-500M

Drug notes:

About:

Jobs: